期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
卷 8, 期 6, 页码 2050-+出版社
ELSEVIER
DOI: 10.1016/j.jaip.2020.02.038
关键词
Angioedema; Control test; Cutoff; Development; Disease control; Patient-reported outcome; Reliability; Screening; Validation; Validity
资金
- GA2LEN network of Urticaria Centers of Reference and Excellence
BACKGROUND: Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although these tools are particularly helpful in clinical studies, they were not designed to determine disease control or to guide treatment decisions. To close this gap, the Angioedema Control Test (AECT) was published recently. OBJECTIVE: To test the AECT for its validity and reliability, and to identify a cutoff value to aid treatment decisions. METHODS: Two AECT versions with a recall period of 4 weeks (AECT-4wk) and 3 months (AECT-3mo) were tested for their internal consistency and test-retest reliability, convergent and known-groups validity as well as screening accuracy in 81 patients with RA with bradykinin-mediated angioedema, mast cell mediator-mediated angioedema, or idiopathic angioedema. RESULTS: Both AECT versions showed excellent internal consistency reliability with a Cronbach alpha value of more than 0.85 and test-retest reliability with an intraclass correlation co-efficient greater than 0.9. The convergent validity of both AECT versions was high. Both tools showed strong correlations with anchors of disease control, angioedema frequency, and health -related quality of life. A stratification of AECT scores into different levels of disease control together with a receiver -operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions. CONCLUSIONS: The AECT is the first valid and reliable patient-reported outcome measure to assess disease control in patients with RA. (c) 2020 American Academy of Allergy, Asthma & Immunology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据